Algernon Pharmaceuticals Inc.
AGN
CNSX
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -139.15% | 65.19% | 27.49% | 83.77% | 227.54% |
| Total Depreciation and Amortization | 37.78% | -26.32% | -25.93% | -61.00% | -52.63% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 110.44% | -80.05% | -77.09% | -99.73% | -989.27% |
| Change in Net Operating Assets | 114.04% | -86.22% | -70.62% | -178.05% | -891.74% |
| Cash from Operations | 90.53% | 12.54% | -363.19% | -7.49% | -142.60% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -100.00% | -352.38% | -- | 30.95% | 8,607.54% |
| Cash from Investing | -92.65% | -352.38% | -- | 30.95% | 8,607.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -100.00% | -- | 249.64% | -99.29% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 67.15% | -- |
| Cash from Financing | -100.00% | -100.00% | -- | 127.03% | -99.23% |
| Foreign Exchange rate Adjustments | -196.97% | 20.00% | 300.00% | -- | 1,200.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.72% | -11,706.25% | -364.34% | 95.82% | 148.44% |